Cargando…
Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey
Sequential endocrine therapy (ET) is recommended for postmenopausal women with hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐negative (HER2−) metastatic breast cancer (mBC) and without visceral symptoms. Chemotherapy (CT) can be considered after sequential ETs, but is asso...
Autores principales: | Lin, Peggy L., Hao, Yanni, Xie, Jipan, Li, Nanxin, Zhong, Yichen, Zhou, Zhou, Signorovitch, James E., Wu, Eric Q. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735772/ https://www.ncbi.nlm.nih.gov/pubmed/26686532 http://dx.doi.org/10.1002/cam4.580 |
Ejemplares similares
-
Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US
por: Xie, Jipan, et al.
Publicado: (2015) -
Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study
por: Li, Nanxin, et al.
Publicado: (2015) -
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015) -
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021) -
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)